Lubomir Sokol, MD, PhD

Where You Are:

Lubomir Sokol, MD, PhD

Medical Oncology

For Consultation Requests or Referrals: (888) 860-2778


          •  Internal Medicine - Medical Oncology
          •  Internal Medicine - Hematology

          •  University of South Florida, Tampa, FL - Medical Oncology/Hematology
          •  University of Alabama, Birmingham, AL - Molecular Biology
          •  Czechoslovak Academy of Sciences, Prague, Czechoslovakia - Molecular Genetics
          •  Charles University of Prague, Czechoslovakia - Clinical Oncology
          •  Charles University of Prague, Czechoslovakia - Radiation Oncology

          •  Louisiana State University, Lafayette, LA - Internal Medicine
          •  Charles University of Prague, Czechoslovakia - Radiation Oncology

          •  Charles University of Prague, Czechoslovakia - MD

  • Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Jan. Pubmedid: 25605368.

  • Wu H, Bui MM, Leston DG, Shao H, Sokol L, Sotomayor EM, Zhang L. Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas. BMC Cancer. 2014 Dec;14:900. Pubmedid: 25465716. Pmcid: PMC4265495.

  • Harrington L, Sokol L, Holdener S, Shao H, Zhang L. Cutaneous gamma-delta T-cell lymphoma with central nervous system involvement: report of a rarity with review of literature. J Cutan Pathol. 2014 Dec;41(12):936-943. Pubmedid: 25292289.

  • Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L. Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years. Cancers (Basel). 2014 Nov;6(4):2275-2295. Pubmedid: 25405526. Pmcid: PMC4276966.

  • Sokol L. Hope for orphan lymphoproliferative and histiocytic diseases on the horizon?. Cancer Control. 2014 Oct;21(4):260-261. Pubmedid: 25310207.

  • Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014 Oct;21(4):279-289. Pubmedid: 25310209.

  • Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014 Oct;21(4):322-327. Pubmedid: 25310213.

  • Dalia S, Shao H, Sagatys E, Cualing H, Sokol L. Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control. 2014 Oct;21(4):290-300. Pubmedid: 25310210.

  • Deaver D, Horna P, Cualing H, Sokol L. Pathogenesis, diagnosis, and management of kikuchi-fujimoto disease. Cancer Control. 2014 Oct;21(4):313-321. Pubmedid: 25310212.

  • Zhang L, Zhou J, Sokol L. Hereditary and acquired hemophagocytic lymphohistiocytosis. Cancer Control. 2014 Oct;21(4):301-312. Pubmedid: 25310211.

  • Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Sep;7(1):11. Pubmedid: 24456586. Pmcid: PMC4016573.

  • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 4.2014. J Natl Compr Canc Ne. 2014 Sep;12(9):1282-1303. Pubmedid: 25190696.

  • Zhang L, Ramchandren RM, Papenhausen P, Loughran TP, Sokol L. Transformed aggressive ??-variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations. Eur J Haematol. 2014 Sep;93(3):260-264. Pubmedid: 24635703.

  • Tees MT, Sokol L. Novel Immunotherapies for B-Cell Lymphomas and Leukemias. Am J Ther. 2014 Sep. Pubmedid: 25237982.

  • Luria L, Nguyen J, Zhou J, Jaglal M, Sokol L, Messina JL, Coppola D, Zhang L. Manifestations of gastrointestinal plasmablastic lymphoma: A case series with literature review. World J Gastroenterol. 2014 Sep;20(33):11894-11903. Pubmedid: 25206297.

  • Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014 Aug;93(8):1305-1312. Pubmedid: 24590536.

  • Dalia S, Price S, Forsyth P, Sokol L, Jaglal M. What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?. Leuk Lymphoma. 2014 Jul;1-3. Pubmedid: 24882264.

  • Wu H, Zhang L, Shao H, Sokol L, Sotomayor E, Letson D, Bui MM. Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience. Brit J Haematol. 2014 Jul;166(1):60-68. Pubmedid: 24673481.

  • Deaver D, Cauthen A, Cohen G, Sokol L, Glass F. Excimer laser in the treatment of mycosis fungoides. J Am Acad Dermatol. 2014 Jun;70(6):1058-1060. Pubmedid: 24775402.

  • Yadav BS, George P, Sharma SC, Gorsi U, McClennan E, Martino MA, Chapman J, Chen LM, Prakash G, Malhotra P, Tantravahi SK, Glenn MJ, Werner TL, Baksh K, Sokol L, Morris GJ. Primary non-Hodgkin lymphoma of the ovary. Semin Oncol. 2014 Jun;41(3):e19-e30. Pubmedid: 25023360.

  • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 2.2014. J Natl Compr Canc Ne. 2014 Jun;12(6):916-946. Pubmedid: 24925202.

  • Horna P, Deaver DM, Qin D, Moscinski LC, Sotomayor EM, Glass LF, Sokol L. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis. J Clin Pathol. 2014 May;67(5):431-436. Pubmedid: 24319102.

  • Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr;99(4):450-456. Pubmedid: 24584873.

  • Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar;38(3):316-322. Pubmedid: 24374145.

  • Deaver D, Naghashpour M, Sokol L. Kikuchi-fujimoto disease in the United States: three case reports and review of the literature [corrected]. Mediterr J Hematol Infect Dis. 2014 Jan;6(1):e2014001. Pubmedid: 24455110. Pmcid: PMC3894840.

  • Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014;2:16. Pubmedid: 25279222. Pmcid: PMC4181623.

  • McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One. 2014;9(12):e114249. Pubmedid: 25469886. Pmcid: PMC4254997.

  • Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Rapid infusion rituximab for maintenance therapy: is it feasible?. Leuk Res Treatment. 2013 Nov;2013:629283. Pubmedid: 24288618. Pmcid: PMC3833187.

  • Horna P, Hamill JR, Sokol L, Glass LF. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient. J Am Acad Dermatol. 2013 Nov;69(5):e274-e276. Pubmedid: 24124865.

  • Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A. 2013 Oct;110(40):16127-16132. Pubmedid: 24043769. Pmcid: PMC3791697.

  • Mailloux AW, Zhang L, Moscinski L, Bennett JM, Yang L, Yoder SJ, Bloom G, Wei C, Wei S, Sokol L, Loughran TP, Epling-Burnette PK. Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. J Immunol. 2013 Oct;191(7):3578-3593. Pubmedid: 24014875.

  • Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013 Sep;37(9):1107-1115. Pubmedid: 23809055.

  • Zhang Y, Zhang L, Jin X, Zhao H, Hao X, Peker D, Wei S, Sokol L, Moscinski L. Bone marrow involvement as initial presentation of CD8 cytotoxic peripheral T-cell lymphoma with CD20 coexpression and relatively indolent clinical course. Leuk Lymphoma. 2013 May;54(5):1113-1116. Pubmedid: 23035635.

  • Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clin Cancer Res. 2013 May;19(13):3659-3670. Pubmedid: 23659971.

  • Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr;21(4):1097-1103. Pubmedid: 23179489.

  • Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38? MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr;27(4):977-980. Pubmedid: 23032694.

  • Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A. miR-21 mediates hematopoietic suppression in MDS by activating TGF-? signaling. Blood. 2013 Apr;121(15):2875-2881. Pubmedid: 23390194. Pmcid: PMC3624935.

  • Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Ne. 2013 Mar;11(3):257-272. Pubmedid: 23486452.

  • Venner CP, Woltosz JW, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF, Karsan A. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 2013 Mar;98(3):409-413. Pubmedid: 22929976. Pmcid: PMC3659949.

  • Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb;32(9):1110-1120. Pubmedid: 22525275. Pmcid: PMC3751397.

  • Zhang L, Sotomayor EM, Papenhausen PR, Shao H, Moscinski LC, Sandin RL, Caceres G, Valenica H, Malafa M, List AF, Sokol L. Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly. Leuk Lymphoma. 2013 Jan;54(1):205-208. Pubmedid: 22694793.

  • Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Ne. 2012 Dec;10(12):1487-1498. Pubmedid: 23221787.

  • McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. Erythropoietin receptor signaling is membrane raft dependent. PLoS One. 2012 Aug;7(4):e34477. Pubmedid: 22509308. Pmcid: PMC3317978.

  • Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Res. 2012 Aug;72(16):4204-4213. Pubmedid: 22761337.

  • Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control. 2012 Jul;19(3):236-244. Pubmedid: 22710899.

  • Tombleson RL, Ho V, Sokol L, Pinilla J, Wetzstein GA. Optimizing premedications in the prevention of bendamustine infusion-related reactions. Cancer Control. 2012 Jul;19(3):245-247. Pubmedid: 22710900.

  • Bello C, Sokol L. B-cell non-hodgkin lymphoma: targeting in on the future. Cancer Control. 2012 Jul;19(3):171-172. Pubmedid: 22710892.

  • Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res. 2012 May;36(5):581-587. Pubmedid: 22386729. Pmcid: PMC3312981.

  • Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother. 2012 Apr;61(4):523-533. Pubmedid: 21983879.

  • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.

  • Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb;30(6):631-636. Pubmedid: 22271479.

  • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.

  • Naghashpour M, Setoodeh R, Moscinski L, Bergier G, McCardle T, Glass F, Sokol L. Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sj?gren syndrome. Am J Dermatopathol. 2011 Dec;33(8):855-857. Pubmedid: 22042261.

  • Sokol L. Fox and Blimp in NK-cell lymphoma. Blood. 2011 Sep;118(12):3192-3193. Pubmedid: 21940827.

  • Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-260. Pubmedid: 21658652.

  • Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's lymphomas. J Natl Compr Canc Ne. 2011 May;9(5):484-560. Pubmedid: 21550968.

  • Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, McGraw K, Clark JA, Sigua CA, Chen DT, Moscinski L, Croce CM, List AF. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Brit J Haematol. 2011 Apr;153(1):24-32. Pubmedid: 21332710. Pmcid: PMC4294220.

  • Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Mantzaris G, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011 Feb;71(3):955-963. Pubmedid: 21189329. Pmcid: PMC3032816.

  • van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010 Aug;28(23):3701-3708. Pubmedid: 20625121.

  • Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leuk Res. 2010 Jun;34(6):821-823. Pubmedid: 19819015.

  • Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Ne. 2010 Mar;8(3):288-334. Pubmedid: 20202462.

  • Johns ME, Moscinski LC, Sokol L. Phenytoin-associated lymphoadenopathy mimicking a peripheral T-cell lymphoma. Mediterr J Hematol Infect Dis. 2010;2(2):e2010028. Pubmedid: 21415974. Pmcid: PMC3033141.

  • Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009 Aug;106(31):12974-12979. Pubmedid: 19470455. Pmcid: PMC2722346.

  • Kiss R, Polg?r T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett. 2009 Jul;19(13):3598-3601. Pubmedid: 19447617. Pmcid: PMC2812898.

  • Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 2009 Apr;113(14):3226-3234. Pubmedid: 19075187. Pmcid: PMC2665892.

  • Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008 Dec;112(12):4694-4698. Pubmedid: 18791165. Pmcid: PMC2597136.

  • Alekshun T, Rezania D, Ayala E, Cualing H, Sokol L. Skeletal muscle peripheral T-cell lymphoma. J Clin Oncol. 2008 Jan;26(3):501-503. Pubmedid: 18202425.

  • Sokol L, List A. Immunomodulatory therapy for myelodysplastic syndromes. Int J Hematol. 2007 Nov;86(4):301-305. Pubmedid: 18055335.

  • Sokol L, Loughran TP. Large granular lymphocyte leukemia. Curr Hematol Malig Rep. 2007 Oct;2(4):278-282. Pubmedid: 20425381.

  • Alekshun T, Tao J, Sokol L. Aggressive T-cell large granular lymphocyte leukemia: A case report and review of the literature. Am J Hematol. 2007 Jun;82(6):481-485. Pubmedid: 17205534.

  • Alekshun T, Sokol L. Diseases of large granular lymphocytes. Cancer Control. 2007 Apr;14(2):141-150. Pubmedid: 17387299.

  • Rezania D, Sokol L, Cualing H. Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control. 2007 Apr;14(2):112-123. Pubmedid: 17387296.

  • Rezania D, Sokol L, Cualing H. Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control. 2007 Apr;14(2):112-123.

  • Behera M, Kumar A, Soares H, Sokol L, Djulbegovic B. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control. 2007 Apr;14(2):160-166. Pubmedid: 17387301.

  • Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins R, Kerr I, Nguyen AN, Xu Y, Platanias LC, List AF, Higgins LS, Verma A. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood. 2006 Dec;108(13):4170-4177. Pubmedid: 16940419. Pmcid: PMC1895446.

  • Kurtin S, Sokol L. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes. Cancer Control. 2006 Dec;13 Suppl:26-31. Pubmedid: 17242664.

  • Sokol L, Loughran TP J. Large granular lymphocyte leukemia. Oncologist. 2006 Mar;11(3):263-273. Pubmedid: 16549811.

  • Naing A, Sokol L, List A. Developmental therapeutics for myelodysplastic syndromes. J Natl Compr Canc Netw. 2006 Jan;4(1):78-82. Pubmedid: 16403406.

  • Alekshun T, Lundbye J, Sokol L, Dailey M. Use of bivalirudin to treat heparin-induced thrombocytopenia in a patient with idiopathic giant-cell myocarditis. Conn Med. 2006;70(2):69-71. Pubmedid: 16768056.

  • Sokol L, Agrawal D, Loughran TP Jr.. Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk Res. 2005 Apr;29(4):381-387. Pubmedid: 15725471.

  • Sokol L, Agosti SJ. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Am J Hematol. 2004 Feb;75(2):107-109. Pubmedid: 14755378.

  • McIlwain L, Sokol L, Moscinski L, Saba H. Acute myeloid leukemia mimicking primary testicular neoplasm. Presentation of a case with review of literature. Eur J Haematol. 2003 Apr;70(4):242-245. Pubmedid: 12656749.

  • Sokol L, Loughran TP J. Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas. Curr Treat Options Oncol. 2003;4(4):289-296. Pubmedid: 12943609.

  • Sokol L, Stueben ET, Jaikishen J, Lamarche MB. Turner syndrome associated with acquired von Willebrand disease, primary biliary cirrhosis, and inflammatory bowel disease. Am J Hematol. 2002 Jul;70(3):257-259. Pubmedid: 12116986.

  • Sokol L, Prchal J. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 2002;346(20):1584-1586. Pubmedid: 12017159.

T/NK cell lymphoma/Leukemia Polycythemia Myelodysplastic syndromes

TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions